TrialThe Journal of infectious diseases2023

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.

Zourab Bebia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.